PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLevoleucovorin
Levoleucovorin
Khapzory, Levoleucovorin (levoleucovorin) is a small molecule pharmaceutical. Levoleucovorin was first approved as Fusilev on 2008-03-07.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Khapzory, Levoleucovorin (discontinued: Fusilev, Khapzory, Levoleucovorin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levoleucovorin
Tradename
Company
Number
Date
Products
KHAPZORYAcrotech BiopharmaN-211226 RX2018-10-19
1 products, RLD, RS
Show 1 discontinued
Levoleucovorin calcium
Tradename
Company
Number
Date
Products
FUSILEVAcrotech BiopharmaN-020140 DISCN2008-03-07
3 products, RLD
LEVOLEUCOVORIN CALCIUMAllerganN-208723 DISCN2016-09-29
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
khapzoryNew Drug Application2024-12-12
levoleucovorinANDA2023-08-01
levoleucovorin calciumANDA2023-08-29
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Levoleucovorin, Khapzory, Acrotech Biopharma
115410122039-03-25DP
ATC Codes
No data
HCPCS
Code
Description
J0641
Injection, levoleucovorin, not otherwise specified, 0.5 mg
J0642
Injection, levoleucovorin (khapzory), 0.5 mg
Clinical
Clinical Trials
1488 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——81268146619478
AdenocarcinomaD000230——451084018183
Pancreatic neoplasmsD010190EFO_0003860C2552963118165
LeukemiaD007938—C9530844736154
NeoplasmsD009369—C8076702423154
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.021684546131
Lymphoid leukemiaD007945—C9121634044119
Stomach neoplasmsD013274EFO_0003897C1624661917106
LymphomaD008223—C85.917662118103
Neoplasm metastasisD009362EFO_0009708—1241201470
Show 28 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0255129—7101
Rectal neoplasmsD012004——215425—599
Colonic neoplasmsD003110—C18173438—786
RecurrenceD012008——18337—154
Non-hodgkin lymphomaD008228—C85.972310—341
Hepatocellular carcinomaD006528—C22.03209—433
Pancreatic ductal carcinomaD021441——14175—133
Gastrointestinal neoplasmsD005770—C26.917131—326
Hiv infectionsD015658EFO_0000764B20528—924
SyndromeD013577——965—220
Show 106 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C5668———13
Multiple myelomaD009101—C90.067———11
Myeloproliferative disordersD009196—D47.138———10
Mantle-cell lymphomaD020522—C83.1—10———10
Burkitt lymphomaD002051—C83.7110———10
Breast neoplasmsD001943EFO_0003869C5045———9
SarcomaD012509——36———9
MelanomaD008545——75———8
Digestive system neoplasmsD004067——64———8
Hodgkin diseaseD006689—C8126———7
Show 135 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A3————3
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.21————1
ThrombocytosisD013922—D75.831————1
OsteomyelitisD010019EFO_0003102M861————1
Skin neoplasmsD012878EFO_0004198C441————1
MalariaD008288EFO_0001068B541————1
Plasma cell leukemiaD007952—C90.11————1
Pharyngeal neoplasmsD010610—C14.01————1
Wasting syndromeD019282——1————1
Weight lossD015431——1————1
Show 21 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pre-eclampsiaD011225EFO_0000668O14————33
Diet therapyD004035——————22
Acquired immunodeficiency syndromeD000163EFO_0000765B20————22
Memory disordersD008569——————22
EclampsiaD004461—O15————22
Healthy dietD000072001——————22
HypercholesterolemiaD006937——————22
OverweightD050177—E66.3————22
AggressionD000374EFO_0003015—————11
AtaxiaD001259—R27.0————11
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLevoleucovorin
INNcalcium levofolinate
Description
Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O
Identifiers
PDB—
CAS-ID68538-85-2
RxCUI—
ChEMBL IDCHEMBL1908841
ChEBI ID63606
PubChem CID6006
DrugBankDB00650
UNII ID778XL6VBS8 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Khapzory – Spectrum Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Fusilev – Spectrum Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 537 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,912 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use